ArticleAntimicrobial agents and chemotherapy2015
Rate of FKS Mutations among Consecutive Candida Isolates Causing Bloodstream Infection.
Article in Antimicrobial agents and chemotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 56 citations in OpenAlex.
- Prevalence and molecular basis of resistance to echinocandins among clinical Candida glabrata isolates in Guangdong province, China.BMC microbiology · 2025Article
- A benchmark dataset for validatingMicrobiology spectrum · 2025Article
- Review
- Epidemiology of Invasive Candidiasis.Clinical epidemiology · 2024Review
- Successful Rezafungin Treatment of an Azole-Resistant Chronic Mucocutaneous Candidiasis in a STAT-1 Gain-of-Function Patient.Journal of clinical immunology · 2023Article
- Whole-Genome Sequence Analysis ofJournal of fungi (Basel, Switzerland) · 2023Article
- Novel Therapeutic Approaches to Invasive Candidiasis: Considerations for the Clinician.Infection and drug resistance · 2023Review
- Characteristics, risk factors, and outcomes of bloodstreamThe Journal of international medical research · 2023Article
- The impact of COVID-19 on antimicrobial prescription and drug resistance in fungi and bacteria.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2022Article
- Crosstalk between the calcineurin and cell wall integrity pathways prevents chitin overexpression in Candida albicans.Journal of cell science · 2021Article
- Narrow mutational signatures drive acquisition of multidrug resistance in the fungal pathogen Candida glabrata.Current biology : CB · 2021Article
- Deciphering the epidemiology of invasive candidiasis in the intensive care unit: is it possible?Infection · 2021Review
- Antifungal Susceptibility Testing Identifies the Abdominal Cavity as a Source of Candida glabrata-Resistant Isolates.Antimicrobial agents and chemotherapy · 2021Article
- Trends of the Epidemiology of Candidemia in Switzerland: A 15-Year FUNGINOS Survey.Open forum infectious diseases · 2021Article
- Resistance to Echinocandins Complicates a Case ofJournal of fungi (Basel, Switzerland) · 2021Article
- Role and Interpretation of Antifungal Susceptibility Testing for the Management of Invasive Fungal Infections.Journal of fungi (Basel, Switzerland) · 2020Review
- Article
- Review on Current Status of Echinocandins Use.Antibiotics (Basel, Switzerland) · 2020Review
- Risk factors for candidemia: a prospective matched case-control study.Critical care (London, England) · 2020Article
- Amphotericin B Induction with Voriconazole Consolidation as Salvage Therapy forAntimicrobial agents and chemotherapy · 2019Article
Corrections and comments
- Erratum issued
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Precise FKS mutation rates among Candida species are undefined because studies have not systematically screened consecutive, disease-causing isolates. The Sensititre YeastOne (SYO) assay measures echinocandin MICs against Candida with less variability than reference broth microdilution methods. However, clinical breakpoint MICs may overstate caspofungin nonsusceptibility compared to other agents. Our objectives were to determine Candida FKS mutation rates by studying consecutive bloodstream isolates and to determine if discrepant susceptibility results were associated with FKS mutations. FKS hot spots were sequenced in echinocandin-intermediate and -resistant isolates and those from patients with breakthrough candidemia or ≥ 3 days of prior echinocandin exposure. Overall, 453 isolates from 384 patients underwent susceptibility testing; 16% were echinocandin intermediate or resistant. Intermediate susceptibility rates were higher for Candida glabrata than for other species (P < 0.0001) and higher for caspofungin than for other agents (P < 0.0001). Resistance rates were similar between agents. FKS mutations were detected in 5% of sequenced isolates and 2% of isolates overall. Corresponding rates among C. glabrata isolates were 8% and 4%, respectively. Among Candida albicans isolates, rates were 5% and <1%, respectively. Mutations occurred exclusively with prior echinocandin exposure and were not detected in other species. Isolates with discrepant susceptibility results did not harbor FKS mutations. Mutation rates among isolates resistant to ≥ 2, 1, and 0 agents were 75%, 13%, and 0%, respectively. In conclusion, FKS mutations were uncommon among non-C. glabrata species, even with prior echinocandin exposure. Discrepancies in echinocandin susceptibility by SYO testing were not driven by mutations and likely reflect imprecise caspofungin clinical breakpoints.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.